This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Badimon JJ et al. (1990) Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest 85: 1234–1241
Hovingh GK et al. (2004) A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease. J Am Coll Cardiol 44: 1429–1435
Barter PJ et al. for the ILLUMINATE Investigators (2007) Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357: 2109–2122
van der Steeg WA et al. (2008) High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol 51: 634–642
Forrest MJ et al. (2007) Torcetrapib-induced blood pressure elevation is independent of cholesteryl ester transfer protein inhibition and is accompanied by an increase in circulating aldosterone levels [abstract #4020]. In Late-breaking basic science abstracts: from the American Heart Association Scientific Sessions 2007 Orlando, Florida November 4–7, 2007. Circ Res 101: 1204–1211
Acknowledgements
The synopsis was written by Alexandra King, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
JJP Kastelein has received Speakers' Bureau honoraria and research support from Merck, Pfizer, and Roche. In addition, he has acted as Consultant for Merck, Pfizer, Roche, and Novartis. M Vergeer declared no competing interests.
Rights and permissions
About this article
Cite this article
Vergeer, M., Kastelein, J. Anacetrapib: new hope for cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia. Nat Rev Cardiol 5, 302–303 (2008). https://doi.org/10.1038/ncpcardio1190
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpcardio1190
This article is cited by
-
Dyslipidemia in type 2 diabetes mellitus
Nature Reviews Endocrinology (2009)